Retatrutide
A profile on the "Triple Agonist" (GLP-1, GIP, and Glucagon), representing the next generation of weight loss peptides.
Retatrutide
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist. It targets three distinct receptors:
- GLP-1: Satiety and insulin secretion.
- GIP: Lipid metabolism and insulin sensitivity.
- Glucagon (GCGR): Energy expenditure.
While Semaglutide is a single agonist (GLP-1) and Tirzepatide is a dual agonist (GLP-1/GIP), Retatrutide activates the Glucagon receptor as well. This unique addition forces the body to burn more calories at rest, leading to weight loss results that surpass both of its predecessors in clinical trials (up to 24% body weight loss).
Quick Specs
| Property | Value |
|---|---|
| Active Compound | Retatrutide |
| Half-Life | ~6 Days |
| Mechanism | Triple Agonist (GLP-1 / GIP / GCGR) |
| Administration | Subcutaneous (SubQ) |
Mechanism of Action
The addition of the Glucagon component is the game changer. Normally, Glucagon raises blood sugar, which seems counterintuitive for diabetes. However, in this specific triple-combination, it increases the metabolic rate (thermogenesis) and liver fat breakdown without destabilizing glucose control (thanks to the GLP-1 and GIP countering it).
It essentially suppresses appetite and turns up the body's furnace simultaneously.
Pharmacokinetics & Dosing
Dosing Protocol
Because of its potency, starting low is mandatory to assess heart rate response.
- Frequency: Once Weekly.
- Titration:
- Month 1: 2mg weekly.
- Month 2: 4mg weekly.
- Month 3+: Adjust based on tolerance (Max 12mg).
Primary Effects
1. Superior Weight Loss
Clinical data shows weight loss speeds roughly 50% faster than Semaglutide.
2. Liver Fat Reduction
Exceptionally effective at stripping fat from the liver (treating Fatty Liver Disease).
3. Energy Expenditure
Users report feeling less "cold" and lethargic compared to Semaglutide, as the metabolic rate is upregulated rather than downregulated.
Side Effects & Harm Reduction
Heart Rate Monitor:
Cardiac Stress: The Glucagon receptor activation increases heart rate. Clinical trials showed an average increase of 5-10 BPM in resting heart rate. If you have arrhythmia or heart conditions, Retatrutide may be risky.
1. GI Distress
Nausea, vomiting, and diarrhea occur, similar to other GLP-1s, but often reported as milder than Semaglutide due to the GIP component.
2. Muscle Wasting
Because weight loss is so rapid, the risk of losing muscle tissue is high. High protein intake (1g per lb of bodyweight) and resistance training are non-negotiable.
Tracking Retatrutide
Using the Anabolic Tracker app:
- Inventory: Add Retatrutide.
- Scheduling: Once Weekly.
- Metrics: Track Resting Heart Rate (Vital) and Weight.
- Notes: Log any palpitations or sustained heart rate elevations.
Disclaimer:
This guide is for informational purposes only. Retatrutide is an investigational drug currently in Phase 3 trials.